Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand
MWN-AI** Summary
Aurora Cannabis Inc., a leading global player in the medical cannabis sector, has recently announced a significant expansion of its medical product portfolio in Australia and New Zealand. This strategic move is designed to enhance patient and prescriber access to a diverse selection of high-quality, scientifically-backed cannabis products, thereby reinforcing Aurora's leadership in key international markets.
The expansion introduces new offerings in New Zealand, including THC flower products such as Big Wave™, Night Ride™, and the balanced strain Half Moon™, with the latter expected to be available in the first quarter of fiscal year 2027. In Australia, four new resin cartridges will also debut: Chemango™ Kush, Cosmic Cream™, Lunar Express™, and Soul Train Haze™. These products are derived from Aurora's proprietary genetics and are manufactured at the company's state-of-the-art EU-GMP and TGA-GMP certified facilities, ensuring adherence to stringent quality standards.
Stanley Sack, Interim Managing Director of MedReleaf Australia, articulated the company's commitment to meeting the evolving needs of patients and prescribers in these regions, emphasizing the importance of delivering reliable, diversified product formats to enhance patient care.
Aurora's expansion strategy is framed by a broader commitment to long-term global growth, with Australia identified as one of its largest medical cannabis markets. The company aims not only to expand its product offerings but also to enhance the accessibility and reliability of its products to meet the needs of patients and healthcare professionals.
Overall, this expansion is a key element of Aurora's mission to improve patient care through quality cannabis offerings and exemplifies the company's dedication to becoming a trusted choice in the international medical cannabis landscape.
MWN-AI** Analysis
Aurora Cannabis Inc. (NASDAQ: ACB) is making significant strides in its global medical growth strategy through its recent expansion in Australia and New Zealand. This initiative is crucial for investors to monitor as it underscores Aurora's commitment to tapping into high-margin markets with burgeoning demand for cannabis products.
The launch of new THC flower and resin products, such as Big Wave™ and Chemango™ Kush, highlights Aurora's strategic focus on diversifying its offerings. This tailored approach not only enhances patient choice but also reinforces the company's position in one of the largest international medical cannabis markets. The company's insistence on high-quality, science-backed products provides a competitive edge, particularly in regions with strict regulatory frameworks.
Investors should focus on the potential revenue growth stemming from this portfolio expansion. The Australian and New Zealand markets are witnessing a steady increase in patient registrations and product prescriptions, reflecting a growing acceptance of medical cannabis. With Aurora’s established brand reputation and proven regulatory compliance, the expansion could be a catalyst for rapid growth in sales, especially as more products roll out in the following months.
However, it is essential to consider the broader market landscape. Competition in the medical cannabis sector is intensifying, with various firms vying for market share. Aurora must remain vigilant in maintaining product quality and reliable supply chains, as these are critical to building lasting relationships with healthcare professionals and patients alike.
In conclusion, Aurora's recent moves signal a robust growth trajectory, supported by its strategic portfolio expansion in Australia and New Zealand. Investors should monitor developments in these regions closely, as successful execution could translate into significant long-term financial returns for the company.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand
Canada NewsWire
NASDAQ | TSX: ACB
Launch reinforces Aurora's leadership position across key international markets
EDMONTON, AB, Feb. 11, 2026 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is expanding its Aurora® medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products. The expansion underscores the company's ongoing dedication to meeting the unique needs of patients and healthcare professionals in the region, reflecting Aurora's strategic focus on long-term global growth.
The expansion in New Zealand this month includes two new THC flower products – Big Wave™, Night Ride ™, as well as the balanced strain, Half Moon™ coming soon in Q1 FY27. The brand will also debut four new resin cartridges in Australia this month including, Chemango™ Kush, Cosmic Cream™, Lunar Express™, and Soul Train Haze™.
"With Australia being one of our largest international medical cannabis market, both Australia and New Zealand remain a top priority for Aurora, and we are deeply committed to our continued investment across the region," says Stanley Sack, Interim Managing Director of MedReleaf Australia. "As patient needs evolve, so does our responsibility to deliver high?quality, diversified product formats that support prescribers in delivering better care. Our focus on quality and reliable supply reflects our dedication to ensuring patients have meaningful access to the products they depend on."
Each new product is derived from Aurora's proprietary genetics, and manufactured at the company's leading EU-GMP and TGA-GMP certified facilities in Canada, ensuring the highest standards of quality and safety.
New Zealand Launches:
- Big Wave™ – Flower, Hybrid, THC 26%, CBD <1%
- Night Ride™ – Flower, Indica, THC 29%, CBD <1%
- Half Moon™ – Flower, Hybrid, THC 9%, CBD 13%
Australia Launches:
- Chemango™ Kush – Resin Cartridge, Indica, THC 780mg/g, CBD <10mg/g
- Cosmic Cream™ – Resin Cartridge, Indica, THC 780 mg/g, CBD <10mg/g
- Lunar Express™ - Resin Cartridge, Indica, THC 780mg/g, CBD <10mg/g
- Soul Train Haze™ – Resin Cartridge, Sativa, THC 780mg/g, CBD <10mg/g
Aurora remains a trusted choice for prescribers and patients around the globe. With a broad portfolio of high-quality medical cannabis, proven regulatory expertise, and strong leadership across a dozen markets, Aurora continues to raise the bar for supporting patient care.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. The company also holds a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's portfolio expansion in Australia and New Zealand and benefits for patients, the Company's commitment to continued investment in those markets, and the Company's strategic focus on long-term global growth.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
SOURCE Aurora Cannabis Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2026/11/c8469.html
FAQ**
How does the expansion of Aurora Cannabis Inc. ACB's medical portfolio in Australia and New Zealand align with its long-term global growth strategy?
What specific patient needs and healthcare challenges does Aurora Cannabis Inc. ACB aim to address with its new product offerings in these markets?
What measures is Aurora Cannabis Inc. ACB implementing to ensure the consistent quality and safety of its new products manufactured at its EU-GMP and TGA-GMP certified facilities?
With Australia being a key market, how does Aurora Cannabis Inc. ACB plan to differentiate its product lines from competitors in the Australian and New Zealand medical cannabis markets?
**MWN-AI FAQ is based on asking OpenAI questions about Aurora Cannabis Inc. (TSXC: ACB:CC).
NASDAQ: ACB:CC
ACB:CC Trading
13.07% G/L:
$1.99 Last:
3,301,272 Volume:
$1.76 Open:
